Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07668232
NA

Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation

Sponsor: South Valley University

View on ClinicalTrials.gov

Summary

Posterior urethral valve is the main cause of bladder outlet obstruction in male infants and the most common cause of obstructive uropathy leading to chronic renal failure and end-stage renal disease in children.The incidence of posterior urethral valve is approximately 1:7,000-8,000 live births.

Official title: Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve Ablation: A Comparative Prospective Randomized Study

Key Details

Gender

MALE

Age Range

3 Years - 12 Years

Study Type

INTERVENTIONAL

Enrollment

52

Start Date

2025-01-01

Completion Date

2025-12-30

Last Updated

2026-06-25

Healthy Volunteers

No

Interventions

DRUG

Mirabegron

To assess the efficacy and the safety of Mirabegron and Oxybutynin drugs after posterior urethral valve ablation regarding: the Effect on upper and lower urinary tract and Febrile UTI recurrence.

Locations (1)

Qina University hospital, South Valley University Hospital

Qina, South Valley, Egypt